We are live on ! Find out more
HALO icon

Halozyme

603 hedge funds and large institutions have $8.75B invested in Halozyme in 2025 Q3 according to their latest regulatory filings, with 112 funds opening new positions, 186 increasing their positions, 239 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more first-time investments, than exits

New positions opened: 112 | Existing positions closed: 52

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

52% more call options, than puts

Call options by funds: $52.5M | Put options by funds: $34.7M

45% more capital invested

Capital invested by funds: $6.05B → $8.75B (+$2.69B)

9% more funds holding

Funds holding: 551603 (+52)

7.59% more ownership

Funds ownership: 94.38%101.97% (+7.6%)

22% less repeat investments, than reductions

Existing positions increased: 186 | Existing positions reduced: 239

Holders
603
Holders Change
+52
Holders Change %
+9.44%
% of All Funds
7.89%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.07%
New
112
Increased
186
Reduced
239
Closed
52
Calls
$52.5M
Puts
$34.7M
Net Calls
+$17.9M
Net Calls Change
+$12.8M

HALO Hedge Fund Activity: Q3 2025 in Review

603 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q3 2025, worth a combined $8.75B — up 45% from $6.05B a quarter earlier.

Buyers outnumbered sellers: 112 funds opened new HALO positions and 52 closed out — a net gain of 60 holders — while 186 added to existing stakes and 239 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $108M. The largest seller was State Street, cutting an estimated $60.8M.

  • 603 institutional investors held Halozyme (HALO) as of Q3 2025, up from 551 in Q2 2025.
  • Funds reported $8.75B of Halozyme stock for Q3 2025, up 45% quarter-over-quarter.
  • 112 funds opened new Halozyme positions in Q3 2025 and 52 closed out, a net change of +60 holders.
  • The largest Halozyme buyer in Q3 2025 was D.E. Shaw & Co, an estimated $108M added.
  • The largest Halozyme seller in Q3 2025 was State Street, an estimated $60.8M sold.

Based on aggregated 13F filings for Q3 2025.